Emergent Biosolutions Inc  

(Public, NYSE:EBS)   Watch this stock  
Find more results for EBS
31.02
+0.59 (1.94%)
May 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 29.00 - 31.08
52 week 19.31 - 31.75
Open 29.81
Vol / Avg. 345,144.00/231,934.00
Mkt cap 1.19B
P/E 66.56
Div/yield     -
EPS 0.47
Shares 38.36M
Beta 1.05
Inst. own 81%
Aug 5, 2015
Q2 2015 Emergent BioSolutions Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 1, 2015
Emergent BioSolutions Inc at Jefferies Global Healthcare Conference Add to calendar
May 22, 2015
Emergent BioSolutions Inc Annual Shareholders Meeting (Estimated)
May 21, 2015
Emergent BioSolutions Inc Annual Shareholders Meeting - Webcast
May 14, 2015
Emergent BioSolutions Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 Emergent BioSolutions Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 Emergent BioSolutions Inc Earnings Release
May 6, 2015
Emergent BioSolutions Inc at Credit Suisse Antibody Day
Mar 26, 2015
Emergent BioSolutions Inc at Maidstone Life Sciences Cancer Immunotherapy: A Long-Awaited Reality Conference
Mar 10, 2015
Emergent BioSolutions Inc at Credit Suisse Under Followed Opportunities Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -33.82% 8.16%
Operating margin -44.49% 12.90%
EBITD margin - 20.11%
Return on average assets -9.27% 4.67%
Return on average equity -15.82% 7.05%
Employees 1,280 -
CDP Score - -

Address

400 Professional Dr Ste 400
GAITHERSBURG, MD 20879-3457
United States - Map
+1-240-6313200 (Phone)
+1-240-6313203 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense division and BioSciences division. The BioDefense division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or bio-warfare and targets the infectious disease, anthrax. Its programs include a pipeline of investigational product candidates and one marketed product, BioThrax (Anthrax Vaccine Adsorbed). The Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. Its products include WinRho SDF, HepaGam B, VARIZIG and Episil.

Officers and directors

Fuad El-Hibri Executive Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Daniel J Abdun-Nabi President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Robert G. Kramer Sr. Executive Vice President - Corporate Services Division, Chief Financial Officer and Treasurer
Age: 57
Bio & Compensation  - Reuters
Adam Havey Executive Vice President and President - BioDefense Division
Age: 44
Bio & Compensation  - Reuters
Barry A. Labinger Executive Vice President, President - Biosciences Division
Age: 51
Bio & Compensation  - Reuters
Ronald B. Richard Lead Independent Director
Age: 59
Bio & Compensation  - Reuters
Sue Bailey M.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Zsolt Harsanyi Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Jerome M. Hauer Independent Director
Age: 63
Bio & Compensation  - Reuters
George A. Joulwan Independent Director
Age: 75
Bio & Compensation  - Reuters